Key result
Macitentan, a second-generation endothelin receptor antagonist, is reviewed for its safety, efficacy, and clinical utility in the treatment of pulmonary arterial hypertension.
Population
Patients with pulmonary arterial hypertension
Design
Review
Authors
Loading...
Supports expanded PAH therapies; leaves open optimal sequencing and long-term durability in broader populations.
This review summarizes the mechanism of action, pharmacokinetics, safety, and efficacy of macitentan, a second-generation endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Davila et al. (2016) conducted a review in Pulmonary arterial hypertension. Macitentan was evaluated. Macitentan, a second-generation endothelin receptor antagonist, is reviewed for its safety, efficacy, and clinical utility in the treatment of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: